Pumitamig用于腺癌的II 期 / III 期研究｜NCT07221149

一分钟看懂

这是一项关于腺癌的II 期 / III 期研究，登记的药物或干预包括Pumitamig；Folfox；Capox；Nivolumab，当前状态为招募中。登记地点显示中国北京、福州、广州、南宁等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。

Pumitamig；Folfox；Capox；Nivolumab · II 期 / III 期

登记的基本范围为不限性别，年龄18 岁；另列出8项专业入选条件，需结合英文原文并由研究团队确认。

登记记录列出7项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。

以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。

* Participants must be previously untreated with systemic treatment for advanced/metastatic disease, histologically or cytologically confirmed advanced or metastatic gastric cancer (GC), gastroesophageal junction adenocarcinoma (GEJC) or distal esophageal aden
* Participants must have a documented programmed cell death-(ligand)1 (PD-L1) ≥ 1 or \< 1 status for Phase 2, and document PD-L1 ≥ 1 status for the Phase 3 part of the study.
* Participants must have documented human epidermal growth factor receptor 2 (HER2)-negative cancer, as determined according to local guidelines.
* Participants must have measurable disease as defined by RECIST v1.1.
Exclusion Criteria
* Participants must not have untreated known central nervous system (CNS) metastases.
* Participants must not have significant cardiovascular disease, such as myocardial infarction, unstable angina, arterial thrombosis, cerebrovascular accident within 6 months prior to randomization, uncontrolled hypertension (≥ 160 systolic, ≥ 100 diastolic mm
* Participants must not have evidence of major coagulation disorders (eg, hemophilia).

请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。

登记号：NCT07221149；登记信息更新于 2026-09-30。